AKRO

Akero Therapeutics New Analyses For Efruxifermin Shows Rapid, Substantial Liver Fat Reduction In NASH Patients

Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH

Can Akero Therapeutics (AKRO) Run Higher on Strong Earnings Estimate Revisions?

Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Akero Therapeutics: A NASH Pureplay With Differentiated Mid Stage Data

Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C

Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients